Each pharmaceutical marketing firm that employs or compensates a pharmaceutical representative who is engaged in marketing, promoting or providing information regarding a legend drug for human use in this state shall ensure that such pharmaceutical representative discloses, in writing, to a prescribing practitioner or pharmacist, each time such pharmaceutical representative makes contact with the prescribing practitioner or pharmacist:

1. (1) The list price of a legend drug when such pharmaceutical representative provides information concerning the legend drug to such prescribing practitioner or pharmacist based on the dose and quantity of such legend drug as described in the medication package insert; and
2. (2) Information on the variation efficacy of the legend drug marketed to different racial and ethnic groups, if such information is available.

(P.A. 23-171, S. 5; P.A. 24-80, S. 4.)

History: P.A. 24-80 substantially amended provisions including by transferring duties from pharmaceutical representative to pharmaceutical marketing firm, effective May 30, 2024.